Antibodies targeting CCR2
ZA202402859BActive Publication Date: 2026-10-28GRANITE BIO AG
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- ZA202402859
- Authority / Receiving Office
- ZA · ZA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-10-27
- Filing Date
- 2024-04-12
- Publication Date
- 2026-10-28
- Estimated Expiration
- 2042-10-25
Abstract
The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.
Need to check novelty before this filing date? Find Prior Art